Advanced search
Publication Cover
Future Neurology Volume 8, 2013 - Issue 1
Submit an article Journal homepage
46
Views
0
CrossRef citations to date
0
Altmetric
Review

Emerging Genomic Biomarkers In Migraine

Saras Menon1 Genomics Research Centre, Griffith Health Institute, Parklands Drive, Southport, Queensland, Australia
&
Lyn Griffiths1 Genomics Research Centre, Griffith Health Institute, Parklands Drive, Southport, Queensland, AustraliaCorrespondence[email protected]
Pages 87-101 | Published online: 14 Dec 2012

References

  • International Headache Society. The international classification of headache disorders (2nd Edition). Cephalalgia24(Suppl. 1), 1–160 (2004).
  • Cerbo R , PesareM, AuriliaC, RondelliV, BarbantiP. Socio-economic costs of migraine. J. Headache Pain2, S15–S19 (2001).
  • Bloudek LM , StokesM, BuseDCet al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J. Headache Pain13(5), 361–378 (2012).
  • Olesen J , GustavssonA, SvenssonM, WittchenHU, JonssonB. The economic cost of brain disorders in Europe. Eur. J. Neurol.19(1), 155–162 (2012).
  • Mathew NT . Pathophysiology, epidemiology, and impact of migraine. Clin. Cornerstone4(3), 1–17 (2001).
  • Aap L . Pial circulation and spreading depression of activity in cerebral cortex. J. Neurophysiol.7, 391–396 (1944).
  • Lauritzen M . Cortical spreading depression in migraine. Cephalagia21, 757–760 (2001).
  • Moskowitz MA . Trigeminovascular system. Cephalalgia12(3), 127–128 (1992).
  • Ward TN . Migraine diagnosis and pathophysiology. Continuum (Minneap. Minn.)18(4), 753–763 (2012).
  • Chasman DI , SchurksM, AnttilaVet al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat. Genet.43(7), 695–698 (2011).
  • Freilinger T , AnttilaV, De VriesBet al. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat. Genet.44(7), 777–782 (2012).
  • Maher BH , GriffithsLR. Identification of molecular genetic factors that influence migraine. Mol. Genet. Genomics285(6), 433–446 (2011).
  • Wessman M , TerwindtGM, KaunistoMA, PalotieA, OphoffRA. Migraine: a complex genetic disorder. Lancet Neurol.6(6), 521–532 (2007).
  • Schurks M . Genetics of migraine in the age of genome-wide association studies. J. Headache Pain13(1), 1–9 (2012).
  • International Headache Society. The International Classification of headache disorders: (2nd Edition). Cephalalgia24(Suppl. 1), S9–S160 (2004).
  • Montagna P . The genetics of migraine. J. Headache Pain2, S79–S82 (2001).
  • Gallanti A , CardinV, TonelliAet al. The genetic features of 24 patients affected by familial and sporadic hemiplegic migraine. Neurol. Sci.32(Suppl. 1), S141–S142 (2011).
  • Joutel A , BousserMG, BiousseVet al. A gene for familial hemiplegic migraine maps to chromosome 19. Nat. Genet.5(1), 40–45 (1993).
  • Hansen JM , ThomsenLL, OlesenJ, AshinaM. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology71(11), 841–847 (2008).
  • Thomsen LL , EriksenMK, RoemerSF, AndersenI, OlesenJ, RussellMB. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. Brain125(Pt 6), 1379–1391 (2002).
  • Ophoff RA , TerwindtGM, VergouweMNet al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell87(3), 543–552 (1996).
  • De Vries B , FrantsRR, FerrariMD, Van Den Maagdenberg AM. Molecular genetics of migraine. Hum. Genet.126(1), 115–132 (2009).
  • Ducros A , Tournier-LasserveE, BousserMG. The genetics of migraine. Lancet Neurol.1(5), 285–293 (2002).
  • Hans M , LuvisettoS, WilliamsMEet al. Functional consequences of mutations in the human α1A calcium channel subunit linked to familial hemiplegic migraine. J. Neurosci.19(5), 1610–1619 (1999).
  • Tottene A , FellinT, PagnuttiSet al. Familial hemiplegic migraine mutations increase Ca(2+) influx through single human CaV2.1 channels and decrease maximal CaV2.1 current density in neurons. Proc. Natl Acad. Sci. USA99(20), 13284–13289 (2002).
  • Pietrobon D , StriessnigJ. Neurobiology of migraine. Nat. Rev. Neurosci.4(5), 386–398 (2003).
  • Dichgans M , FreilingerT, EcksteinGet al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet366(9483), 371–377 (2005).
  • De Fusco M , MarconiR, SilvestriLet al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit associated with familial hemiplegic migraine type 2. Nat. Genet.33(2), 192–196 (2003).
  • Vahedi K , DepienneC, Le FortDet al. Elicited repetitive daily blindness: a new phenotype associated with hemiplegic migraine and SCN1A mutations. Neurology72(13), 1178–1183 (2009).
  • Vanmolkot KR , BabiniE, De VriesBet al. The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Mutation in brief #957. Hum. Mutat.28(5), 522 (2007).
  • Castro MJ , StamAH, LemosCet al. First mutation in the voltage-gated Nav1.1 subunit gene SCN1A with co-occurring familial hemiplegic migraine and epilepsy. Cephalalgia29(3), 308–313 (2009).
  • Cuenca-Leon E , CorominasR, MontfortMet al. Familial hemiplegic migraine: linkage to chromosome 14q32 in a Spanish kindred. Neurogenetics10(3), 191–198 (2009).
  • Moskowitz MA , BolayH, DalkaraT. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann. Neurol.55(2), 276–280 (2004).
  • Lauritzen M . Pathophysiology of the migraine aura. The spreading depression theory. Brain117(Pt 1), 199–210 (1994).
  • Lashley J , LarsenB, LauritzenM. Related focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Arch. Neurol. (9), 344–352 (1981).
  • Lashley KS . Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neurol. (46), 331–339 (1941).
  • Jen JC , WanJ, PalosTP, HowardBD, BalohRW. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology65(4), 529–534 (2005).
  • Anttila V , StefanssonH, KallelaMet al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat. Genet.42(10), 869–873 (2010).
  • Prescot A , BecerraL, PendseGet al. Excitatory neurotransmitters in brain regions in interictal migraine patients. Mol. Pain5, 34 (2009).
  • Siniatchkin M , SendackiM, MoellerFet al. Abnormal changes of synaptic excitability in migraine with aura. Cereb. Cortex22(10), 2207–2216 (2012).
  • Ayata C . Cortical spreading depression triggers migraine attack: pro. Headache50(4), 725–730 (2010).
  • Eikermann-Haerter K , AyataC. Cortical spreading depression and migraine. Curr. Neurol. Neurosci. Rep.10(3), 167–173.
  • Suzuki M , Van PaesschenW, StalmansIet al. Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. Proc. Natl Acad. Sci. USA107(36), 15963–15968 (2010).
  • Thomsen LL , OlesenJ, RussellMB. Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives. Eur. J. Neurol.10(4), 421–427 (2003).
  • Lafreniere RG , CaderMZ, PoulinJFet al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat. Med.16(10), 1157–1160 (2010).
  • Chae YJ , ZhangJ, AuP, SabbadiniM, XieGX, YostCS. Discrete change in volatile anesthetic sensitivity in mice with inactivated tandem pore potassium ion channel TRESK. Anesthesiology113(6), 1326–1337 (2010).
  • Arne M ay, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J. Cereb. Blood Flow Metab.19, 115–127 (1999).
  • Andres-Enguix I , ShangL, StansfeldPJet al. Functional analysis of missense variants in the TRESK (KCNK18) K channel. Sci. Rep.2, 237 (2012).
  • Fumal A , SchoenenJ. Genetics of migraines: from ionic channels to single nucleotide polymorphisms? Rev. Med. Liege59(6), 367–377 (2004).
  • Wessman M , KaunistoMA, KallelaM, PalotieA. The molecular genetics of migraine. Ann. Med.36(6), 462–473 (2004).
  • Lea RA , ShepherdAG, CurtainRPet al. A typical migraine susceptibility region localizes to chromosome 1q31. Neurogenetics4(1), 17–22 (2002).
  • Lea RA , ShepherdAG, CurtainRPet al. A typical migraine susceptibility region localizes to chromosome. Neurogenetics (4), 17–22 (2002).
  • Bosch MA , KellyMJ, RonnekleivOK. Distribution, neuronal colocalization, and 17β-E2 modulation of small conductance calcium-activated K(+) channel (SK3) mRNA in the guinea pig brain. Endocrinology143(3), 1097–1107 (2002).
  • Chandy KG , FantinoE, WittekindtOet al. Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? Mol. Psychiatry 3(1), 32–37 (1998).
  • Kohler M , HirschbergB, BondCTet al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science273(5282), 1709–1714 (1996).
  • Flink MT , AtchisonWD. Ca2+ channels as targets of neurological disease: Lambert–Eaton syndrome and other Ca2+ channelopathies. J. Bioenerg. Biomembr.35(6), 697–718 (2003).
  • Lea RA , DohyA, JordanK, QuinlanS, BrimagePJ, GriffithsLR. Evidence for allelic association of the dopamine β-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics3(1), 35–40 (2000).
  • Peroutka SJ , WilhoitT, JonesK. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology49(1), 201–206 (1997).
  • Villalon CM , CenturionD, ValdiviaLF, De Vries P, Saxena PR. Migraine: pathophysiology, pharmacology, treatment and future trends. Curr. Vasc. Pharmacol.1(1), 71–84 (2003).
  • Mossner R , WeichselbaumA, MarziniakMet al. A highly polymorphic poly-glutamine stretch in the potassium channel KCNN3 in migraine. Headache45(2), 132–136 (2005).
  • Cox HC , LeaRA, BellisCet al. Variants in the human potassium channel gene (KCNN3) are associated with migraine in a high risk genetic isolate. J. Headache Pain12(6), 603–608 (2011).
  • Bellis C , CoxHC, DyerTDet al. Linkage mapping of CVD risk traits in the isolated Norfolk Island population. Hum. Genet.124(5), 543–552 (2008).
  • Bellis C , CoxHC, OvcaricMet al. Linkage disequilibrium analysis in the genetically isolated Norfolk island population. Heredity (Edinb.).100(4), 366–373 (2008).
  • Mcevoy BP , ZhaoZZ, MacgregorSet al. European and Polynesian admixture in the Norfolk Island population. Heredity (Edinb.).105(2), 229–234 (2010).
  • Nyholt DR , LaforgeKS, KallelaMet al. A high-density association screen of 155 ion transport genes for involvement with common migraine. Hum. Mol. Genet.17(21), 3318–3331 (2008).
  • Dobler T , SpringaufA, TovornikSet al. TRESK two-pore-domain K+ channels constitute a significant component of background potassium currents in murine dorsal root ganglion neurones. J. Physiol.585(Pt 3), 867–879 (2007).
  • Panconesi A , SicuteriR. Headache induced by serotonergic agonists – a key to the interpretation of migraine pathogenesis? Cephalalgia17(1), 3–14 (1997).
  • Treatment of acute cluster headache with sumatriptan. The Sumatriptan Cluster Headache Study Group. N. Engl. J. Med.325(5), 322–326 (1991).
  • Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N. Engl. J. Med.325(5), 316–321 (1991).
  • Ferrari MD , RoonKI, LiptonRB, GoadsbyPJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358(9294), 1668–1675 (2001).
  • Kim WK , KimHS, KimWJet al. Serotonin transporter gene polymorphism and migraine in the Korean population. Headache45(8), 1056–1060 (2005).
  • Silberstein SD . Serotonin (5-HT) and migraine. Headache34(7), 408–417 (1994).
  • Porter RH , BenwellKR, LambHet al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol.128(1), 13–20 (1999).
  • Schaerlinger B , HickelP, EtienneN, GuesnierL, MaroteauxL. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br. J. Pharmacol.140(2), 277–284 (2003).
  • Schmuck K , UllmerC, KalkmanHO, ProbstA, LubbertH. Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur. J. Neurosci.8(5), 959–967 (1996).
  • Supornsilpchai W , SanguanrangsirikulS, ManeesriS, SrikiatkhachornA. Serotonin depletion, cortical spreading depression, and trigeminal nociception. Headache46(1), 34–39 (2006).
  • Corominas R , SobridoMJ, RibasesMet al. Association study of the serotoninergic system in migraine in the Spanish population. Am. J. Med. Genet. B. Neuropsychiatr. Genet.153B(1), 177–184 (2010).
  • Ferrari MD , SaxenaPR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia13(3), 151–165 (1993).
  • Hamel E . Serotonin and migraine: biology and clinical implications. Cephalalgia27(11), 1293–1300 (2007).
  • Juhasz G , ZsombokT, ModosEAet al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain106(3), 461–470 (2003).
  • Marziniak M , MossnerR, SchmittA, LeschKP, SommerC. A functional serotonin transporter gene polymorphism is associated with migraine with aura. Neurology64(1), 157–159 (2005).
  • Todt U , FreudenbergJ, GoebelIet al. Variation of the serotonin transporter gene SLC6A4 in the susceptibility to migraine with aura. Neurology67(9), 1707–1709 (2006).
  • Borroni B , BrambillaC, LiberiniPet al. Functional serotonin 5-HTTLPR polymorphism is a risk factor for migraine with aura. J. Headache Pain6(4), 182–184 (2005).
  • Kotani K , ShimomuraT, ShimomuraF, IkawaS, NanbaE. A polymorphism in the serotonin transporter gene regulatory region and frequency of migraine attacks. Headache42(9), 893–895 (2002).
  • Yilmaz M , ErdalME, HerkenH, CatalolukO, BarlasO, BayazitYA. Significance of serotonin transporter gene polymorphism in migraine. J. Neurol. Sci.186(1–2), 27–30 (2001).
  • Schurks M , RistPM, KurthT. 5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis. Cephalalgia30(11), 1296–1305 (2010).
  • Buchwalder A , WelchSK, PeroutkaSJ. Exclusion of 5-HT2A and 5-HT2C receptor genes as candidate genes for migraine. Headache36(4), 254–258 (1996).
  • Johnson MP , LeaRA, CurtainRP, MacmillanJC, GriffithsLR. An investigation of the 5-HT2C receptor gene as a migraine candidate gene. Am. J. Med. Genet. B. Neuropsychiatr. Genet.117B(1), 86–89 (2003).
  • Racchi M , LeoneM, PorrelloEet al. Familial migraine with aura: association study with 5-HT1B/1D, 5-HT2C, and hSERT polymorphisms. Headache44(4), 311–317 (2004).
  • Erdal ME , HerkenH, YilmazM, BayazitYA. Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine. J. Neurol. Sci.188(1–2), 99–101 (2001).
  • Naito Y , IshiiM, NagamineAet al. Association of the A-1438G polymorphism in serotonin 2A receptor in migraine with aura among Japanese patients. Biol. Pharm. Bull.33(10), 1751–1753 (2010).
  • Mackenzie A , QuinnJ. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc. Natl Acad. Sci. USA96(26), 15251–15255 (1999).
  • Schurks M , RistPM, KurthT. STin2 VNTR polymorphism in the serotonin transporter gene and migraine: pooled and meta-analyses. J. Headache Pain11(4), 317–326 (2010).
  • Liu H , LiuM, WangYet al. Association of 5-HTT gene polymorphisms with migraine: a systematic review and meta-analysis. J. Neurol. Sci.305(1–2), 57–66 (2011).
  • Johnson MP , GriffithsLR. A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach. J. Hum. Genet.50(12), 607–610 (2005).
  • Akerman S , GoadsbyPJ. Dopamine and migraine: biology and clinical implications. Cephalalgia27(11), 1308–1314 (2007).
  • Fanciullacci M , AlessandriM, Del Rosso A. Dopamine involvement in the migraine attack. Funct. Neurol.15(Suppl. 3), S171–S181 (2000).
  • Marmura MJ . Use of dopamine antagonists in treatment of migraine. Curr. Treat. Options Neurol.14(1), 27–35 (2012).
  • D‘andrea G , GranellaF, PeriniF, FarruggioA, LeoneM, BussoneG. Platelet levels of dopamine are increased in migraine and cluster headache. Headache46(4), 585–591 (2006).
  • Shukla R , KhannaVK, VinodP, Sankhwar Ml, Yadav RS. Platelet dopamine: D2 receptor binding in patients with migraine. Cephalalgia29(5), 532–538 (2009).
  • Barbanti P , FabbriniG, RicciAet al. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia20(1), 15–19 (2000).
  • Bergerot A , StorerRJ, GoadsbyPJ. Dopamine inhibits trigeminovascular transmission in the rat. Ann. Neurol.61(3), 251–262 (2007).
  • Lazarov N , PilgrimC. Localization of D1 and D2 dopamine receptors in the rat mesencephalic trigeminal nucleus by immunocytochemistry and in situ hybridization. Neurosci. Lett.236(2), 83–86 (1997).
  • De Sousa SC , KarwautzA, WoberCet al. A dopamine D4 receptor exon 3 VNTR allele protecting against migraine without aura. Ann. Neurol.61(6), 574–578 (2007).
  • Del Zompo M , CherchiA, PalmasMAet al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology51(3), 781–786 (1998).
  • Shepherd Ag LR , HutchinsC, JordanKL, BrimagePJ, GriffithsLR. Dopamine receptor genes and migraine with and without aura: an association study. Headache42(5), 346–351 (2002).
  • Duan J , WainwrightMS, ComeronJMet al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet.12(3), 205–216 (2003).
  • Dichgans M , ForderreutherS, DeiterichM, PfaffenrathV, GasserT. The D2 receptor NcoI allele: absence of allelic association with migraine with aura. Neurology51(3), 928 (1998).
  • Ghosh J , PradhanS, MittalB. Role of dopaminergic gene polymorphisms (DBH 19 bp indel and DRD2 Nco I) in genetic susceptibility to migraine in north Indian population. Pain Med.12(7), 1109–1111 (2011).
  • Mochi M , CevoliS, CortelliPet al. A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-β-hydroxylase genes. Neurol. Sci.23(6), 301–305 (2003).
  • Todt U , NetzerC, ToliatMet al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum. Genet.125(3), 265–279 (2009).
  • Ghosh J , PradhanS, MittalB. Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility. Neuromol. Med. doi:10.1007/s12017-012-8195-9 (2012) (Epub ahead of print).
  • Anthony M . Biochemical indices of sympathetic activity in migraine. Cephalalgia1(2), 83–89 (1981).
  • Gotoh F , KandaT, SakaiF, YamamotoM, TakeokaT. Serum dopamine-β-hydroxylase activity in migraine. Arch. Neurol.33(9), 656–657 (1976).
  • Cubells JF , Van KammenDP, KelleyMEet al. Dopamine β-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum. Genet.102(5), 533–540 (1998).
  • Fernandez F , LeaRA, ColsonNJ, BellisC, QuinlanS, GriffithsLR. Association between a 19 bp deletion polymorphism at the dopamine β-hydroxylase (DBH) locus and migraine with aura. J. Neurol. Sci.251(1–2), 118–123 (2006).
  • Fernandez F , ColsonN, QuinlanS, MacmillanJ, LeaRA, GriffithsR. Association between migraine and a functional polymorphism at the dopamine β-hydroxylase locus. Neurogenetics10(3), 199–208 (2009).
  • Corominas R , RibasesM, CaminaMet al. Two-stage case–control association study of dopamine-related genes and migraine. BMC Med. Genet.10, 95 (2009).
  • Sicuteri F . Dopamine, the second putative protagonist in headache. Headache17(3), 129–131 (1977).
  • Lipton RB , StewartWF. Prevalence and impact of migraine. Neurol. Clin.15(1), 1–13 (1997).
  • Allais G , BenedettoC. Update on menstrual migraine: from clinical aspects to therapeutical strategies. Neurol. Sci.25(Suppl. 3), S229–S231 (2004).
  • Kelman L . Women‘s issues of migraine in tertiary care. Headache44(1), 2–7 (2004).
  • Macgregor EA . Oestrogen and attacks of migraine with and without aura. Lancet Neurol.3(6), 354–361 (2004).
  • Macgregor EA , ChiaH, VohrahRC, WilkinsonM. Migraine and menstruation: a pilot study. Cephalalgia10(6), 305–310 (1990).
  • Silberstein SD , MerriamGR. Estrogens, progestins, and headache. Neurology41(6), 786–793 (1991).
  • Macgregor EA . ‘Menstrual‘ migraine: towards a definition. Cephalalgia16(1), 11–21 (1996).
  • Silberstein SD , MerriamGR. Physiology of the menstrual cycle. Cephalalgia20(3), 148–154 (2000).
  • Greco R , TassorelliC, MangioneASet al. Effect of sex and estrogens on neuronal activation in an animal model of migraine. Headache doi:10.1111/j.1526-4610.2012.02249.x (2012) (Epub ahead of print).
  • Colson NJ , LeaRA, QuinlanS, GriffithsLR. The role of vascular and hormonal genes in migraine susceptibility. Mol. Genet. Metab.88(2), 107–113 (2006).
  • Sacco S , RicciS, DeganD, CaroleiA. Migraine in women: the role of hormones and their impact on vascular diseases. J. Headache Pain13(3), 177–189 (2012).
  • Osterlund MK , GrandienK, KellerE, HurdYL. The human brain has distinct regional expression patterns of estrogen receptor α mRNA isoforms derived from alternative promoters. J. Neurochem.75(4), 1390–1397 (2000).
  • Colson NJ , LeaRA, QuinlanS, MacmillanJ, GriffithsLR. The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics5(2), 129–133 (2004).
  • Oterino A , TorielloM, CayonAet al. Multilocus analyses reveal involvement of the ESR1, ESR2, and FSHR genes in migraine. Headache48(10), 1438–1450 (2008).
  • Kaunisto MA , KallelaM, HamalainenEet al. Testing of variants of the MTHFR and ESR1 genes in 1798 Finnish individuals fails to confirm the association with migraine with aura. Cephalalgia26(12), 1462–1472 (2006).
  • Schurks M , RistPM, KurthT. Sex hormone receptor gene polymorphisms and migraine: a systematic review and meta-analysis. Cephalalgia30(11), 1306–1328 (2010).
  • Colson NJ , LeaRA, QuinlanS, GriffithsLR. No role for estrogen receptor 1 gene intron 1 Pvu II and exon 4 C325G polymorphisms in migraine susceptibility. BMC Med. Genet.7, 12 (2006).
  • Schuit SC , De JongFH, StolkLet al. Estrogen receptor α gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur. J. Endocrinol. Eur. Federat. Endocr. Soc.153(2), 327–334 (2005).
  • Joshi G , PradhanS, MittalB. Role of the oestrogen receptor (ESR1 PvuII and ESR1 325 C->G) and progesterone receptor (PROGINS) polymorphisms in genetic susceptibility to migraine in a North Indian population. Cephalagia30(3), 311–320 (2010).
  • Bell DW , KimSH, GodwinAKet al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int. J. Cancer121(12), 2661–2667 (2007).
  • Haiman CA , DossusL, SetiawanVWet al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res.67(5), 1893–1897 (2007).
  • Rowe SM , CoughlanSJ, MckennaNJet al. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res.55(13), 2743–2745 (1995).
  • Wang T , SharmaSD, FoxN, RossorM, BrownMJ, SharmaP. Description of a simple test for CADASIL disease and determination of mutation frequencies in sporadic ischaemic stroke and dementia patients. J. Neurol. Neurosurg. Psychiatry69(5), 652–654 (2000).
  • Donaldson CJ , CrapanzanoJP, WatsonJC, LevineEA, BatzerMA. PROGINS Alu insertion and human genomic diversity. Mutat. Res.501(1–2), 137–141 (2002).
  • Colson NJ , LeaRA, QuinlanS, MacmillanJ, GriffithsLR. Investigation of hormone receptor genes in migraine. Neurogenetics6(1), 17–23 (2005).
  • Corominas R , RibasesM, Cuenca-LeonE, CormandB, MacayaA. Lack of association of hormone receptor polymorphisms with migraine. Eur. J. Neurol.16(3), 413–415 (2009).
  • Cenni B , PicardD. Ligand-independent activation of steroid receptors: new roles for old players. Trends Endocr. Metab. TEM10(2), 41–46 (1999).
  • Kelly MJ , LevinER. Rapid actions of plasma membrane estrogen receptors. Trends Endocr. Metab. TEM12(4), 152–156 (2001).
  • Graham JR , WolfHG. Mechanism of migraine headache and action of ergotamine tartrate. Arch. Neurol. Psychiatry39, 737–763 (1938).
  • Reuter U , BolayH, Jansen-OlesenIet al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain124(Pt 12), 2490–2502 (2001).
  • Levy D . Migraine pain, meningeal inflammation, and mast cells. Curr. Pain Headache Rep.13(3), 237–240 (2009).
  • Johnson ES . A basis for migraine therapy – the autonomic theory reappraised. Postgraduate Med. J.54(630), 231–243 (1978).
  • Lea R , ColsonN, QuinlanS, MacmillanJ, GriffithsL. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet. Genomics19(6), 422–428 (2009).
  • Silaste ML , RantalaM, SampiM, AlfthanG, AroA, KesaniemiYA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J. Nutr.131(10), 2643–2647 (2001).
  • Evers S , HgkIW, HusstedT. Plasma homocysteine levels in primary headache. In: Headache Pathogenesis: Monoamines, Neuropeptides, Purines, and Nitric Oxide. OlesenJ, EdvinssonL(Eds) . Lippincott-Raven Publishers, PA, USA, 215–218 (1997).
  • Kara I , SazciA, ErgulE, KayaG, KilicG. Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res. Mol. Brain Res.111(1–2), 84–90 (2003).
  • Oterino A , ValleN, BravoYet al. MTHFR T677 homozygosis influences the presence of aura in migraineurs. Cephalalgia24(6), 491–494 (2004).
  • Frosst P , BlomHJ, MilosRet al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet.10(1), 111–113 (1995).
  • Geisel J , ZimbelmannI, SchorrHet al. Genetic defects as important factors for moderate hyperhomocysteinemia. Clin. Chem. Lab. Med.39(8), 698–704 (2001).
  • Lea RA , OvcaricM, SundholmJ, MacmillanJ, GriffithsLR. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med.2, 3 (2004).
  • Kowa H , YasuiK, TakeshimaT, UrakamiK, SakaiF, NakashimaK. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am. J. Med. Genet.96(6), 762–764 (2000).
  • Scher AI , TerwindtGM, VerschurenWMet al. Migraine and MTHFR C677T genotype in a population-based sample. Ann. Neurol.59(2), 372–375 (2006).
  • Marinho C , AlhoI, ArduinoD, FalcaoLM, Bras-NogueiraJ, BichoM. GST M1/T1 and MTHFR polymorphisms as risk factors for hypertension. Biochem. Biophys. Res. Commun.353(2), 344–350 (2007).
  • Schurks M , ZeeRY, BuringJE, KurthT. Interrelationships among the MTHFR 677C>T polymorphism, migraine, and cardiovascular disease. Neurology71(7), 505–513 (2008).
  • Todt U , FreudenbergJ, GoebelIet al. MTHFR C677T polymorphism and migraine with aura. Ann. Neurol.60(5), 621–622 (2006).
  • Rubino E , FerreroM, RaineroI, BinelloE, VaulaG, PinessiL. Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia29(8), 818–825 (2009).
  • Menon S , CoxHC, KuwahataMet al. Association of a Notch 3 gene polymorphism with migraine susceptibility. Cephalalgia31(3), 264–270 (2011).
  • Schwaag S , EversS, SchirmacherA, StogbauerF, RingelsteinEB, KuhlenbaumerG. Genetic variants of the NOTCH3 gene in migraine – a mutation analysis and association study. Cephalalgia26(2), 158–161 (2006).
  • Joutel A , VahediK, CorpechotCet al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet350(9090), 1511–1515 (1997).
  • Joutel A , Tournier-LasserveE. Notch signalling pathway and human diseases. Semin. Cell Dev. Biol.9(6), 619–625 (1998).
  • Federico A , BianchiS, DottiMT. The spectrum of mutations for CADASIL diagnosis. Neurol. Sci.26(2), 117–124 (2005).
  • Hutchinson M , O‘riordanJ, JavedMet al. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann. Neurol.38(5), 817–824 (1995).
  • Lesnik Oberstein SA , Van Den BoomR, MiddelkoopHAet al. Incipient CADASIL. Arch. Neurol.60(5), 707–712 (2003).
  • Smith RA , CurtainR, OvcaricM, TajouriL, MacmillanJ, GriffithsL. Investigation of the NOTCH3 and TNFSF7 genes on C19p13 as candidates for migraine. Open Neurol. J.2, 1–7 (2008).
  • Silvestrini M , CupiniLM, TroisiE, MatteisM, BernardiG. Estimation of cerebrovascular reactivity in migraine without aura. Stroke26(1), 81–83 (1995).
  • Yetkin E , OzisikH, OzcanC, AksoyY, TurhanH. Decreased endothelium-dependent vasodilatation in patients with migraine: a new aspect to vascular pathophysiology of migraine. Coronary Artery Dis.17(1), 29–33 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.